Ranbaxy gets Health Canada nod for cholesterol lowering drug
New Delhi: Ranbaxy Laboratories today said it has received approval from the Health Canada to manufacture and market its generic RAN-Rosuvastatin tablets used for
lowering cholesterol in the Canadian market.
"Ranbaxy Pharmaceuticals Canada Inc (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd has received approval from Health Canada to manufacture and market
RAN-Rosuvastatin tablets to the Canadian healthcare system," Ranbaxy Laboratories said in a statement.
Health Canada is the country`s federal regulatory body of drugs and health. RAN-Rosuvastatin tablets are generic version of Astra Zeneca`s Crestor tablets.
Commenting on the approval RPCI, Canada President and GM Paul Drake said: "The finished dosage form was developed, and will be manufactured within RLL`s Health Canada approved facilities located in India."
Such a generic formulation is anticipated to have positive economic benefits to the healthcare system of Canada, as well as to all Canadian patients that require Rosuvastatin
therapy, he added.
Ranbaxy Laboratories is a part of the Daiichi Sankyo Group, which had acquired majority stake in the domestic firm in 2008 for a total outgo of around Rs 22,000 crore.
More from India
More from World
More from Sports
More from Entertaiment
- DNA: US army's joint exercise with Indian Army and their consolation on Uri attack
- DNA: Analysis of Indus water treaty between India and Pakistan
- India to activate lazer walls on LOC to stop infiltration
- India- America joint military exercise begins in Ranikhet
- EPFO to launch new online system for pensions and PFs soon
- Donald Trump praises Hindu community's contributions to US
- Five takeaways from Sushma Swaraj's speech at UN General Assembly
- Reliance Jio impact: Vodafone offers 10 GB data at 1 GB rate
- 7 scenarios Pak will face directly if India scraps Indus Waters Treaty – Read details
- REALITY CHECK of WhatsApp message: How common man can sign petition to declare Pakistan a terror state